Overview

Oxytocin Versus, Sublingual Misoprostol in the Secondary Prevention of Postpartum Hemorrhage After Vaginal Delivery

Status:
Not yet recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

Researchers sought to see how oxytocin versus, sublingual misoprostol affected estimated and measured blood loss during vaginal delivery in women who had blood loss >300 ml .

Phase:

N/A

Details

Lead Sponsor:

Aswan University Hospital

Treatments:

Misoprostol
Oxytocin